Drug Profile
Recombinant human hyaluronidase-based subcutaneous therapeutic - Roche
Latest Information Update: 21 May 2019
Price :
$50
*
At a glance
- Originator Roche
- Developer Halozyme Therapeutics; Roche
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 20 Feb 2018 Phase-I clinical trials in Undefined indication (SC)